Evidence map›Paper›PMID 40791526›Full record

ArticlebioRxiv : the preprint server for biology2025

An ultra-long heavy chain bovine antibody neutralizes SARS-CoV-2 and reacts broadly with sarbecoviruses.

Theocharis Tsoleridis, Chengcheng Fan, Emily J Park, Joshua D Duncan, Parul Sharma, Sophie Wartnaby, Joseph G Chappell, Anja Kipar, Eleanor G Bentley, Adam Kirby and 15 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Theocharis TsoleridisWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0000-0002-9685-6318
Chengcheng FanDivision of Biology and Biological Engineering, California Institute of Technology; Pasadena, CA 91125, USA.ORCID 0000-0003-4213-5758
Emily J ParkWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.
Joshua D DuncanWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0000-0002-8638-4628
Parul SharmaDept of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool; Liverpool, L3 5RF, UK.
Sophie WartnabyWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0009-0009-3710-1773
Joseph G ChappellWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0000-0002-8205-4242
Anja KiparDept of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool; Liverpool, L3 5RF, UK.
Eleanor G BentleyDept of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool; Liverpool, L3 5RF, UK.
Adam KirbyDept of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool; Liverpool, L3 5RF, UK.
Ximeng HanDept of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool; Liverpool, L3 5RF, UK.
Christopher M ColemanWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0000-0002-7306-8407
Igor SantosThe Pirbright Institute; Woking, GU24 0NF, UK.
Dalan BaileyThe Pirbright Institute; Woking, GU24 0NF, UK.
Andrew I FlyakDivision of Biology and Biological Engineering, California Institute of Technology; Pasadena, CA 91125, USA.ORCID 0000-0002-8722-479X
C Patrick McClureWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0000-0002-1710-1049
Semi RhoDivision of Biology and Biological Engineering, California Institute of Technology; Pasadena, CA 91125, USA.
Daniel X JohanssonDept of Clinical Neuroscience, Centre for Molecular Medicine, Karolinska Institutet; Stockholm, 171 76, Sweden.ORCID 0000-0002-4228-1301
Mats A A PerssonDept of Clinical Neuroscience, Centre for Molecular Medicine, Karolinska Institutet; Stockholm, 171 76, Sweden.ORCID 0000-0002-5118-6584
Alex W TarrWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0000-0003-1009-0823
David HaigWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0000-0002-9661-9603
James P StewartDept of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool; Liverpool, L3 5RF, UK.
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology; Pasadena, CA 91125, USA.ORCID 0000-0002-2277-3990
Richard A UrbanowiczWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0000-0002-2461-4993
Jonathan K BallWolfson Centre for Global Virus Research, The University of Nottingham; Nottingham, NG7 2UH, UK.ORCID 0000-0001-5773-8733

Funding

A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responsesP01AI165075 · NIAID · ROCKEFELLER UNIVERSITY · PI BJORKMAN, PAMELA J · 2022 to 2023
$10.7M
Virology CoreP01AI138938 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2018 to 2022
$8.4M
NIAID NIH HHS P01 AI138938NIAID NIH HHS P01 AI165075NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P30 GM133894
6 · The paper itself

Abstract

The ongoing threat of new SARS-CoV-2 variants and other sarbecoviruses has driven efforts to develop broadly neutralizing monoclonal antibodies (mAbs). This study used immunized cattle, known for producing antibodies with ultra-long CDRH3 domains, to generate 33 mAbs, ten of which had ultra-long CDRH3s (>50 amino acids). Of these, mAbs P7 and 99, demonstrated broad and potent neutralization. Notably, mAb P7 neutralized all tested variants, including SARS-CoV-1, with IC

Identifiers

PMID40791526
PMCPMC12338560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.